Nora Cazzagon
A5073783997- Liver Diseases and Immunity
- Liver Disease Diagnosis and Treatment
- Pediatric Hepatobiliary Diseases and Treatments
- Gallbladder and Bile Duct Disorders
- Liver Disease and Transplantation
- Hepatitis B Virus Studies
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Hepatitis C virus research
- Hepatitis Viruses Studies and Epidemiology
- Hepatocellular Carcinoma Treatment and Prognosis
- Liver physiology and pathology
- Trace Elements in Health
- Celiac Disease Research and Management
- Pancreatitis Pathology and Treatment
- Drug Transport and Resistance Mechanisms
- Inflammatory Bowel Disease
- Systemic Lupus Erythematosus Research
- Gastroesophageal reflux and treatments
- Nanoparticle-Based Drug Delivery
- Systemic Sclerosis and Related Diseases
- Pregnancy and Medication Impact
- Corporate Identity and Reputation
- Microscopic Colitis
- Pharmacological Effects and Toxicity Studies
- Securities Regulation and Market Practices
University of Padua
2016-2025
Azienda Ospedaliera di Padova
2020-2023
Humanitas University
2023
IRCCS Humanitas Research Hospital
2023
ERN GUARD-Heart
2020-2023
ERN RARE-LIVER
2020-2023
University Medical Center Hamburg-Eppendorf
2023
Universität Hamburg
2023
Assistance Publique – Hôpitaux de Paris
2018-2022
King's College Hospital
2022
Background & AimsThe Primary Biliary Cholangitis (PBC) Obeticholic Acid (OCA) International Study of Efficacy (POISE) randomized, double-blind, placebo-controlled trial demonstrated that OCA reduced biomarkers associated with adverse clinical outcomes (ie, alkaline phosphatase, bilirubin, aspartate aminotransferase, and alanine aminotransferase) in patients PBC. The objective this study was to evaluate time first occurrence liver transplantation or death the POISE open-label extension vs...
•Under real-world conditions, OCA was effective in ~43% of patients who were non-responders to UDCA, according Poise criteria.•Patients with cirrhosis showed lower efficacy (29.5%), mainly attributed reduced tolerability and higher discontinuation rate.•Patients overlap AIH-PBC a comparable pure PBC, ALT reduction at 6 months.•Most PBC are still need additional therapy if aiming normalise liver biochemistry. Background & aimsObeticholic acid (OCA) is the second-line treatment approved for...
Background and Aims: Normal alkaline phosphatase (ALP) levels in ursodeoxycholic acid (UDCA)-treated patients with primary biliary cholangitis (PBC) are associated better long-term outcome. However, second-line therapies currently recommended only when ALP remain above 1.5 times the upper limit of normal (×ULN) after 12-month UDCA. We assessed whether, considered good responders to UDCA, were significant survival gains. Approach Results: performed a retrospective cohort study 1047 PBC who...
Chronic immunosuppression is associated with increased and more severe viral infections. However, little known about the association between acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Our aim was to describe clinical course of patients immunosuppressed autoimmune hepatitis (AIH) during disease 2019 (COVID-19) infection in Italy. study a case series AIH treated immunosuppression, who tested positive for SARS-CoV-2 March 2020 outbreak COVID-19. Ten from seven different...
Summary Background Obeticholic acid (OCA) and fibrates are second‐line therapies for patients with primary biliary cholangitis (PBC) an inadequate response to ursodeoxycholic (UDCA). Aim To know whether OCA fibrates, administered together in combination UDCA, have additive beneficial effects difficult‐to‐treat PBC. Methods PBC treated ≥3 months (bezafibrate or fenofibrate) due failure of either therapy were included a multicentre, uncontrolled retrospective cohort study. Changes biochemical...
Background and Aims Liver fibrosis holds a relevant prognostic meaning in primary biliary cholangitis (PBC). Noninvasive evaluation using vibration‐controlled transient elastography (VCTE) is routinely performed. However, there limited evidence on its accuracy at diagnosis PBC. We aimed to estimate the diagnostic of VCTE assessing advanced (AF) disease presentation Approach Results collected data from 167 consecutive treatment‐naïve PBC patients who underwent liver biopsy (LB) six Italian...
Abstract Background & Aims Evidence for the benefit of scheduled imaging early detection hepatobiliary malignancies in primary sclerosing cholangitis (PSC) is limited. We aimed to compare different follow‐up strategies PSC with hypothesis that regular improves survival. Methods collected retrospective data from 2975 patients 27 centres. Patients were followed start or case clinical 1 January 2000, until death last alive. The endpoint was all‐cause mortality. Results A broad variety...
Background: The natural history of primary biliary cirrhosis (PBC) is still debated. Aims: To evaluate: (i) long-term survival in a large cohort PBC patients observed prospectively at single centre and (ii) mortality relation to baseline characteristics ursodeoxycholic acid (UDCA) treatment. Methods: We considered all consecutive between 1973 2007 (327 subjects; 310 females, 17 males). Results: mean follow-up was 9.1±7.7 years. patients' age diagnosis for representative periods (1973–1980,...